CSIMarket
 



Strongbridge Biopharma plc  (SBBP)
Other Ticker:  
 
 



 

What are Strongbridge Biopharma Plc's Business Segments?



Strongbridge Biopharma plc is a biopharmaceutical company that specializes in developing and commercializing therapies for rare diseases. The company focuses primarily on endocrine disorders and rare neuromuscular diseases. Strongbridge Biopharma offers a range of products and services to meet the needs of patients with these conditions.

Segments:
The company operates in two main segments, namely:

1. Rare Disease-- This segment focuses on the development and commercialization of therapies for endocrine disorders and rare neuromuscular diseases.

2. Commercial-- This segment is responsible for the commercialization of Exserohilum rostratum, a treatment for serious infections caused by the fungus Exserohilum rostratum.

Products:

1. Keveyis - This is an oral medication used to treat hyperkalemic, hypokalemic, and periodic paralysis.

2. Recorlev - Recorlev is a medication used to treat Cushing's syndrome.

3. Macrilen - This is an oral medication used as a diagnostic for growth hormone deficiency (GHD).

4. Veldoreotide - This is an injectable medication used to treat Acromegaly.

Services:

Strongbridge Biopharma offers a range of services that support the development and commercialization of their products. Some of the services they offer include:

1. Medical Affairs- Strongbridge Biopharma's medical affairs team provides medical education and support for physicians, patients, and caregivers.

2. Clinical Trials- Strongbridge Biopharma designs and conducts clinical trials to evaluate the safety and efficacy of their products.

3. Patient Support Programs - Strongbridge Biopharma offers patient support programs that provide education, access to therapy, and other support services to patients.

4. Marketing and Sales- Strongbridge Biopharma's commercial team is responsible for the marketing and sales of their products.

In summary, Strongbridge Biopharma plc is a biopharmaceutical company that offers a range of products and services to meet the needs of patients with rare endocrine disorders and neuromuscular diseases. Their products include Keveyis, Recorlev, Macrilen, and Veldoreotide, and their services include medical affairs, clinical trials, patient support programs, and marketing and sales.
   

Strongbridge Biopharma Plc Tax Rate Companies within the Major Pharmaceutical Preparations Industry


Business Segments Q2
Revenues
(in millions $)
Q2
Income
(in millions $)
(Jun 30 2021)
%
(Profit Margin)
Total 10.04 -13.24 -

Growth rates by Segment Q2
Y/Y Revenue
%
(Jun 30 2021)
Q/Q Revenue
%
Q2
Y/Y Income
%
(Jun 30 2021)
Q/Q Income
%
Total 29.41 % 19.8 % - -

To get more information on Strongbridge Biopharma Plc's Total segment. Select each division with the arrow.


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com